Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-03-20

FDA Approved: BUPRENORPHINE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine from Actavis Pharma, Inc. under ANDA090819, granting regulatory clearance for this generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • buprenorphine (buprenorphine)

Snippet

SUPPL AP for BUPRENORPHINE (BUPRENORPHINE)